new option listings on July 28th » 08:3007/2807/28/21
ACHV, ADES, ALGS, ATCX, BBCP, BTTR, CDAK, CGA, CHMI, CRCT, CRTD, DRTT, EARN, EPS, ESXB, EZM, HMLP, ICL, IMXI, INTT, LIQT, MDWD, PSJ, RTPY, SGTX, SIC, USDP, VIRI, VYGG
New option listings for…
New option listings for July 28th include Achieve Life Sciences Inc (ACHV), Advanced Emissions (ADES), Market Vectors Africa (AFK), Aligos Therapeutics Inc (ALGS), Atlas Technical Consultants Inc (Class A Stock) (ATCX), Concrete Pumping Holdings Inc (BBCP), Better Choice Company Inc (BTTR), CBX (CBX), Codiak BioSciences Inc (CDAK), China Green (CGA), Cherry Hill Mortgage (CHMI), Cricut Inc (CRCT), Creatd Inc (CRTD), WisdomTree High Dividend Fund (DHS), Dirtt Environmental Solutions Ltd (DRTT), Ellington Residential (EARN), WisdomTree SmallCap Earnings Fund (EES), WisdomTree Earnings 500 Fund (EPS), Community Bankers Trust (ESXB), WisdomTree MidCap Earnings Fund (EZM), Hoegh LNG (HMLP), IBO (IBO), Israel Chemicals (ICL), iShares Evolved US Technology ETF (IETC), iShares Edge MSCI Intl Momentum Factor ETF (IMTM), International Money Express Inc (IMXI), inTest (INTT), WisdomTree International Quality Dividend Growth Fund (IQDG), iShares Russell Top 200 (IWL), iShares Russell Top 200 Value (IWX), iShares Dow Jones US (IYY), SPDR Russell 1000 Low Volatility ETF (LGLV), LiqTech (LIQT), MediWound (MDWD), Power Shares Food And Beverage (PBJ), PowerShares S&P 500 Buy Write Portfolio (PBP), PowerShares Dynamic Media Portfolio (PBS), PowerShares FTSE RAFI Developed Markets Ex US Sm Mid Portfolio (PDN), PowerShares Dynamic Building and Construction Portfolio (PKB), PowerShares S&P SmallCap Consumer Discretionary Portfolio (PSCD), Power Shares Dynamic Software Portfolio (PSJ), Powershares Dynamic Large Cap Growth Portfolio (PWB), Powershares Dynamic Large Cap Value Portfolio (PWV), PowerShares FTSE RAFI Developed Markets ex US Portfolio (PXF), PowerShares DWA Basic Materials Momentum Portfolio (PYZ), Reinvent Technology Partners Y (Class A Stock) (RTPY), Sigilon Therapeutics Inc (SGTX), Select Interior Concepts Inc (Class A Stock) (SIC), Presidio Property Trust Inc (Class A Stock) (SQFT), USD Partners (USDP), Virios Therapeutics Inc (VIRI), Vy Global Growth (Class A Stock) (VYGG), WisdomTree Cybersecurity Fund (WCBR), Innovative Technology ETF (XITK), and SPDR NYSE Technology (XNTK).
|Over a week ago|
Codiak management to meet virtually with Evercore ISI » 04:5507/1907/19/21
Virtual Meeting to be…
Virtual Meeting to be held on July 19 hosted by Evercore ISI.
Codiak management to meet virtually with Evercore ISI » 15:5507/1507/15/21
Virtual Meeting to be…
Virtual Meeting to be held on July 19 hosted by Evercore ISI.
VBI Vaccines announces Codiak BioSciences' CFO Linda Bain to join board » 08:2307/0707/07/21
VBI Vaccines (VBIV)…
VBI Vaccines (VBIV) announced that Linda Bain, Chief Financial Officer of Codiak BioSciences has joined its Board of Directors. Ms. Bain is an accomplished financial and business executive with more than two decades of finance, strategy, and board experience in both small and large public companies in the biotechnology and pharmaceutical industry. As CFO of Codiak BioSciences (CDAK), Bain led the company through its initial public offering and first follow-on financing, building on the success of earlier-stage financing rounds. Ms. Bain plays a lead role in establishing Codiak's strategic direction and she built and leads finance and business operations, including investor relations and corporate communications, finance, accounting, facilities and information technology.
|Over a month ago|
Codiak BioSciences expands executive leadership » 08:1606/1506/15/21
Codiak BioSciences announced the promotion of Sriram Sathyanarayanan, Ph.D., who has led Codiak's preclinical research efforts for the past four years to Chief Scientific Officer. Additionally, Konstantin Konstantinov, Ph.D., who has led the company's manufacturing and process sciences since Codiak's inception, has been named Chief Technology Officer. Prior to this appointment, Sathyanarayanan was Senior Vice President, Preclinical Development. Konstantinov most recently held the position of Executive Vice President, Manufacturing and Process Sciences.
Codiak presents new preclinical data from its engEx Platform » 08:3505/1105/11/21
Codiak BioSciences announced new preclinical data from programs from its engEx Platform showing the potential therapeutic applications of engineered exosomes. The data, which include results from the IND-enabling studies for exoASO-STAT6, immune evasion data from Codiak's exoAAV gene therapy platform, data showing the versatility of Codiak's exoVACC vaccine platform, and Codiak's ability to engineer specific cell uptake were presented at the virtual 24th Annual Meeting of the American Society of Gene and Cell Therapy. Codiak's proprietary engEx Platform enables the company to engineer exosomes with distinct properties, load them with various therapeutic molecules and alter tropism so they reach specific cellular targets. Codiak has two programs in clinical development and expects to file an IND for exoASO-STAT6 by the end of the year. exoASO-STAT6 Demonstrates Immune-Mediated Anti-Tumor Activity. Data presented at ASGCT from Codiak's exoASO-STAT6 program confirm results presented earlier this year showing potent local and systemic anti-tumor activity. Exosome-mediated delivery of an ASO results in enhanced uptake and improved silencing of STAT6 in tumor associated macrophages compared to ASO administration without an exosome. This activity, which was evident both in vitro and in vivo and across species, was persistent for up to 10 days and resulted in effective reprogramming of immunosuppressive macrophages to a pro-inflammatory phenotype. Efficacy studies of exoASO-STAT6 in multiple tumor models revealed dose-dependent single-agent activity, including 94% tumor growth inhibition and 60% complete responses at the efficacious dose in a CT26 tumor model and 62% reduction in tumor mass and complete elimination of tumor lesions in an orthotopic model of HCC unresponsive to other immunotherapies. exoVACC Induces Robust, Tunable and Broad Immune Response. The data presented at ASGCT show that this platform enables antigen-specific immune responses that can be modulated through antigen orientation and adjuvant loading. Further, multiple exoVACC vaccine constructs induced superior systemic and tissue-resident immune responses via various routes of administration compared to conventional vaccine formulations in animal models. Immune-Silent Nature of Exosomes Provides Potential Strategy to Enhance AAV Delivery. Codiak presented new data at ASGCT that show that exosomes also have potential utility in overcoming the limitations of current adeno-associated virus vectors used for the delivery of gene therapies. Engineered Exosomes with Altered Cellular Tropism Instigate Preferential Uptake in Neuronal Cells. Results from multiple in vitro and in vivo studies have demonstrated the ability of the engEx Platform to modulate exosome tropism and drive uptake into specific cell types.
Codiak appoints Jennifer Wheler as Chief Medical Officer » 08:0505/1005/10/21
Codiak BioSciences announced the appointment of Jennifer Wheler, M.D. as Chief Medical Officer. Dr. Wheler, who joins the company's Executive Leadership Team and reports to president and CEO Douglas Williams, Ph.D., will provide leadership and direction for Codiak's pipeline of clinical development programs through early-stage trials to global regulatory submissions. Benny Sorensen, M.D., Ph.D., who has led the preclinical to clinical translational work and clinical strategy for Codiak for the past five years will become Senior Vice President, Strategic Projects. Dr. Sorensen will report to president and CEO Douglas Williams and continue as a member of Codiak's Executive Leadership Team. Dr. Wheeler served most recently as chief medical officer of Bicara Therapeutics, where she designed and led the first-in-human Phase I/II trial for the company's bi-functional antibody candidate.
|Over a quarter ago|
Codiak BioSciences Inc trading resumes 13:5204/2204/22/21
Codiak BioSciences Inc trading halted, volatility trading pause 13:4704/2204/22/21
Codiak announces publication of data on exoSTING preclinical development » 07:0904/2204/22/21
Codiak BioSciences announced the online publication of a new manuscript, exoSTING, an extracellular vesicle loaded with STING agonists, promotes tumor immune surveillance, in Communications Biology, a Nature Research publication. exoSTING is a novel engineered exosome therapeutic candidate currently being investigated in a Phase 1/2 clinical trial as a single agent for the treatment of multiple solid tumors. This publication details the findings from the preclinical development program and highlights the potential of exoSTING to stimulate a broad immune response without the detrimental effects on intratumoral T cells observed with other STING agonists. exoSTING is one of two Codiak programs currently in clinical development. Engineered using the company's proprietary engEx(TM) Platform to provide targeted delivery of Codiak's STING agonist to antigen presenting cells (APCs) in the tumor microenvironment, exoSTING demonstrates greater than 100-fold increased potency in in vivo tumor models and increased tumor retention and lower levels of systemic inflammatory cytokine production as compared to free STING agonist. Additionally, exoSTING demonstrates CD8 T-cell preservation, expansion, Th1 polarization and establishment of systemic antigen-specific T-cell mediated immune responses across a wide dose range without evidence of immune ablation as seen with free STING agonists. A Phase 1/2 dose escalation clinical trial of exoSTING is currently underway investigating safety, tolerability, pharmacological activity, and objective tumor response in patients with advanced/metastatic, recurrent, injectable solid tumors, with a focus on tumors likely to be enriched in APCs. Examples of such tumors include metastatic head and neck squamous cell cancer, triple negative breast cancer, anaplastic thyroid carcinoma, and cutaneous squamous cell carcinoma. Safety, biomarker and preliminary efficacy data from the dose-escalation phase of the trial are expected in mid-2021.